Entering text into the input field will update the search result below

Ampio's Ampion flunks another late-stage study; shares down 68% premarket

Jun. 30, 2016 9:26 AM ETAmpio Pharmaceuticals, Inc. (AMPE)By: Douglas W. House, SA News Editor1 Comment
  • Thinly traded micro cap Ampio Pharmaceuticals (NYSE:AMPE) craters 68% premarket on robust volume in response to its announcement that a Phase 3 clinical trial, PIVOT, assessing Ampion, an intra-articular injection for the potential treatment of pain associated with osteoarthritis (OA) of the knee, failed to beat placebo (saline injection).
  • Ampion also failed a Phase 3 study in OA of the knee in 2015. The company says it will meet with the FDA to discuss all of its data.
  • Management will host a conference call at 4:30 pm ET on Tuesday, July 5 to discuss the results.
  • Ampion is a low molecular weight fraction of human serum albumin (HSA). Its main ingredient is an immunomodulatory molecule derived from HSA called aspartyl-alanyl diketopiperazine (DA-DKP). DA-DKP is believed to reduce inflammation by suppressing pro-inflammatory cytokine production in T cells.
  • Previously: Ampio Pharma off 58% premarket on failed trial results (April 20, 2015)

Recommended For You

Comments (1)

Have a tip? Submit confidentially to our News team. Found a factual error? Report here.

Any chance AMPE back on track??
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.